Granules of human eosinophilic leucocytes and their mobilization

Clinical and Experimental Allergy

Volumn 31, Issue 8, 2001, Pages 1173-1188

  Egesten, A ^a,d   Calafat, J ^b   Janssen, H ^b   Knol, E F ^c   Malm, J ^a   Persson, T ^a  

^a LUND UNIVERSITY   (Sweden)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD18 ANTIGEN; CELL PROTEIN; CYTOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PROTEIN; TETRASPANIN;

CELL COMPARTMENTALIZATION; CELL GRANULE; CELL INTERACTION; CELL MEMBRANE; CELL MOTILITY; CELL POPULATION; CELL STRUCTURE; CROSS LINKING; CRYSTAL; CYTOTOXICITY; DEGRANULATION; EOSINOPHIL; EXOCYTOSIS; GENETIC CODE; GENETIC TRANSCRIPTION; GRANULE CELL; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE MIGRATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SECRETORY VESICLE; STEM CELL; TRANSCRIPTION REGULATION;

ANIMALS; CELL DEGRANULATION; CYTOPLASMIC GRANULES; EOSINOPHILS; HUMANS;

EID: 0035726387     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2001.01138.x     Document Type: Review

References (156)

1. Eosinophils
2. Ablation of eosinophil and IgE responses with anti-IL-5 or anti-IL-4 antibodies fails to affect immunity against Schistosoma mansoni in the mouse
3. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
4. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4
5. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth
6. Developmental biology of neutrophils and eosinophils
7. Interleukin-5, eosinophils, and disease
8. Human eosinophil major basic protein, a mediator of allergic inflammation, is expressed by alternative splicing from two promoters
9. The eosinophil peroxidase gene forms a cluster with the genes for myeloperoxidase and lactoperoxidase on human chromosome 17
10. Molecular cloning and characterization of a chromosomal gene for human eosinophil peroxidase
11. Functional characterization of the promoter for the gene encoding human eosinophil peroxidase
12. Localization of the human eosinophil Charcot-Leyden crystal protein (lysophospholipase) gene (CLC) to chromosome 19 and the human ribonuclease 2 (eosinophil-derived neurotoxin) and ribonuclease 3 (eosinophil cationic protein) genes (RNS2 and RNS3) to chromosome 14
13. Rapid evolution of a unique family of primate ribonuclease genes
14. Enhanced expression of the eosinophil-derived neurotoxin ribonuclease (RNS2) gene requires interaction between the promoter and intron
15. Intronic enhancer activity of the eosinophil-derived neurotoxin (RNS2) and eosinophil cationic protein (RNS3) genes is mediated by an NFAT-1 consensus binding sequence
16. The role of transcription factor PU.1 in the activity of the intronic enhancer of the eosinophil-derived neurotoxin (RNS2) gene
17. Human eosinophil Charcot-Leyden crystal protein. Cloning and characterization of a lysophospholipase gene promoter
18. Eosinophil granule proteins in peripheral blood granulocytes
19. Molecular cloning of the human eosinophil-derived neurotoxin: A member of the ribonuclease gene family
20. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes
21. Localization of a molecule immunochemically similar to eosinophil major basic protein in human placenta
22. Formation of Charcot-Leyden crystals by human basophils
23. A novel and highly divergent homolog of human eosinophil granule major basic protein
24. Segregation and packaging of granule enzymes in eosinophilic leukocytes
25. Exocytotic competence and intragranular fusion in cord blood-derived eosinophils during differentiation
26. Localization of granule proteins in human eosinophil bone marrow progenitors
27. Ultrastructural localization of Charcot-Leyden crystal protein in human eosinophils and basophils
28. Eosinophil structure and maturation
29. Human eosinophil lysophospholipase. The sole protein component of Charcot-Leyden crystals
30. Biochemical characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase)
31. The genomic structure of the human Charcot-Leyden crystal protein gene is analogous to those of the galectin genes
32. Selective recognition of mannose by the human eosinophil Charcot-Leyden crystal protein (galectin-10): A crystallographic study at 1.8: A resolution
33. Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily
34. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils
35. Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals
36. The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity
37. The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules
38. Granules of the human neutrophilic polymorphonuclear leukocyte
39. Localization of eosinophil cationic protein, major basic protein and eosinophil peroxidase by immunoelectron microscopic technique
40. Characterization of eosinophils generated in vitro from CD34+ peripheral blood progenitor cells
41. Regulation and processing of a precursor form of eosinophil granule major basic protein (proMBP) in differentiating eosinophils
42. Immunofluorescence analysis of cytokine and granule protein expression during eosinophil maturation from cord blood-derived CD34 progenitors
43. Rapid mobilization of intracellularly stored RANTES in response to interferon-γ in human eosinophils
44. Functional expression of transmembrane 4 superfamily molecules on human eosinophils
45. Cytochemical and ultrastructural identification of a small type granule in human late eosinophils
46. Human eosinophil arylsulfatase B. Structure and activity of the purified tetrameric lysosomal hydrolase
47. Cytoplasmic lipid bodies of human eosinophils: Subcellular isolation and analysis of arachidonate incorporation
48. Arylsulfatase B is present in crystalloid-containing granules of human eosinophil granulocytes
49. Activation of lysosomal acid phosphatase of eosinophil leukocytes
50. Spezifische Mikrogranula in Eosinophilen
51. Localization of the low-Mr subunit of cytochrome b558 in human blood phagocytes by immunoelectron microscopy
52. Evidence for small intracellular vesicles in human blood phagocytes containing cytochrome b558 and the adhesion molecule CD11b/CD18
53. Subcellular localization of TGF-alpha in human eosinophil granulocytes
54. Major histocompatibility complex class II molecules induce the formation of endocytic MIIC-like structures
55. Accessory cell function of human eosinophils. HLA-DR-dependent, MHC-restricted antigen-presentation and IL-1 alpha expression
56. The role of adhesion molecules in human eosinophil and basophil recruitment
57. Eosinophils isolated with two different methods show different characteristics of activation
58. Altered density, metabolism and surface receptors of eosinophils in eosinophilia
59. Granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 greatly enhance the interaction of human eosinophils with opsonized particles by changing the affinity of complement receptor type 3
60. Regulatory effect of cytokines on eosinophil degranulation
61. Eosinophil granulocyte interaction with serum-opsonized particles. Binding and degranulation are enhanced by tumor necrosis factor alpha
62. Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinant human interleukin-5. Part I. Piecemeal degranulation of specific granules and distribution of Charcot-Leyden crystal protein
63. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration
64. Allergen-induced eosinophil cytolysis is a primary mechanism for granule protein release in human upper airways
65. Eosinophil viability during immunoglobulin-induced degranulation
66. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein
67. Phorbol-esterinduced degranulation in adherent human eosinophil granulocytes is dependent on CD11/CD18-leukocyte integrins
68. Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles
69. Release of platelet-activating factor is important for the respiratory burst induced in human eosinophils by opsonized particles
70. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG
71. Ligation of the beta 2 integrin triggers activation and degranulation of human eosinophils
72. A crucial role for beta 2 integrin in the activation of eosinophils stimulated by IgG
73. Mechanism of inhibition of immunoglobulin G-mediated phagocytosis by monoclonal antibodies that recognizes the Mac-1 antigen
74. IgA-induced eosinophil degranulation
75. Human eosinophils express a receptor for secretory component. Role in secretory IgA-dependent activation
76. Interaction with secretory component stimulates effector functions of human eosinophils but not of neutrophils
77. Does IgE bind to and activate eosinophils from patients with allergy?
78. Differential effects of the T helper cell type 2-derived cytokines IL-4 and IL-5 on ligand binding to IgG and IgA receptors expressed by human eosinophils
79. Intracellular expression of Fc gamma RIII (CD16) and its mobilization by chemoattractants in human eosinophils
80. Release of granule proteins by eosinophils from allergic and nonallergic patients with eosinophilia on immunoglobulin-dependent activation
81. High-affinity IgE receptor on eosinophils is involved in defence against parasites
82. Eosinophils: From low- to high-affinity immunoglobulin E receptors
83. Intracellular expression and release of Fc epsilon RI alpha by human eosinophils
84. Human C1q induces eosinophil migration
85. Characterization of a receptor for C5a anaphylatoxin on human eosinophils
86. Evaluation of C3a receptor expression on human leucocytes by the use of novel monoclonal antibodies
87. Effects of interleukin (IL) -3 and IL-5 on human eosinophil degranulation induced by complement components C3a and C5a
88. Binding of immunoglobulin classes to human neutrophils and eosinophils
89. Roles of CD9 molecules in survival and activation of human eosinophils
90. Eosinophil leukocyte degranulation in response to serum-opsonized beads. C5a and platelet-activating factor (PAF) enhance ECP release, with roles for protein kinases A and C
91. A new method for measuring eosinophil activating factors, based on the increased expression of CR3 alpha chain (CD11b) on the surface of activated eosinophils
92. Characteristics of CR3-mediated aggregation in human eosinophils: Effect of priming by platelet-activating factor
93. A surrogate method for assessment of beta (2)-integrin-dependent adhesion of human eosinophils to ICAM-1
94. Three distinct fusion processes during eosinophil degranulation
95. Focal exocytosis by eosinophils - Compound exocytosis and cumulative fusion
96. Studies on blood eosinophils. I. Patients with a transient eosinophilia
97. The mechanisms which produce vacuolated and degranulated eosinophils
98. Regulated exocytosis in immune function: Are SNARE-proteins involved?
99. A survey of GTP-binding proteins and other potential key regulators of exocytotic secretion in eosinophils. Apparent absence of rab3 and vesicle fusion protein homologues
100. Mechanism of membrane damage mediated by human eosinophil cationic protein
101. Interaction of eosinophil granule major basic protein with synthetic lipid bilayers: A mechanism for toxicity
102. The cytotoxic eosinophil cationic protein has ribonuclease activity
103. Recombinant human eosinophil cationic protein. Ribonuclease activity is not essential for cytotoxicity
104. Eosinophil cationic protein/RNase 3 is another RNase A-family ribonuclease with direct antiviral activity
105. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus
106. Synergism between eosinophil cationic protein and oxygen metabolites in killing of schistosomula of Schistosoma mansoni
107. Bactericidal activity of eosinophil peroxidase
108. Diseases due to helminths
109. Damage to Schistosomula mansoni induced directly by eosinophil major basic protein
110. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins
111. Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni
112. Damage to Trichinella spiralis newborn larvae by eosinophil major basic protein
113. Peroxidase-mediated toxicity to schistosomula of Schistosoma mansoni
114. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein
115. Comparative toxicity of the horse eosinophil peroxidase-H2O2-halide system and granule basic proteins
116. Eosinophil infiltration and degranulation in normal human tissue
117. IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection
118. Eosinophil-mediated mammalian tumor cell cytotoxicity. Role of the peroxidase system
119. Eosinophil infiltration of human colonic carcinomas as a prognostic indicator
120. Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma
121. Mechanisms of eosinophil-associated inflammation
122. The effect of purified human eosinophil major basic protein on mammalian ciliary activity
123. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor
124. Eosinophil perox-idase-induced mast cell secretion
125. The idiopathic hypereosinophilic syndrome
126. Eosinophils stimulate fibroblast DNA synthesis
127. Human eosinophils express transforming growth factor alpha
128. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1
129. Identification of interleukin-2 in human peripheral blood eosinophils
130. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils
131. Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product
132. Interleukin 5 synthesis by eosinophils. Association with granules and immunoglobulin-dependent secretion
133. Human eosinophils synthesize and secrete interleukin-6 in vitro
134. Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon γ
135. Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore
136. Constitutive production of IL-4 and IL-10 and stimulated production of IL-8 by normal peripheral blood eosinophils
137. Evidence for expression of eosinophil-associated IL-12 messenger RNA and immunoreactivity in bronchial asthma
138. Human eosinophils elaborate the lymphocyte chemoattractants: IL-16 (lymphocyte chemoattractant factor) and RANTES
139. Association of granulocyte-macrophage colony-stimulating factor with the crystalloid granules of human eosinophils
140. Human eosinophils can express the cytokines tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha
141. Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma
142. Expression of vascular endothelial growth factor by human eosinophils: Upregulation by granulocyte macrophage colony-stimulating factor and interkeuken-5
143. Expression and regulation of monocyte chemoattractant protein-1 by human eosinophils
144. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein
145. Intracellular localization and release of eotaxin from normal eosinophils
146. Localization of human eosinophil granule major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin by immunoelectron microscopy
147. Presence in human eosinophils of a lysophospholipase similar to that found in the pancreas
148. Human eosinophils express, relative to other circulating leukocytes, large amounts of secretory 14-kD phospholipase A2
149. The bactericidal/permeability increasing protein (BPI) is present in specific granules of eosinophils
150. Expression and intracellular localization of the human N-acetylmuramyl-L-alanine amidase, a bacterial cell wall-degrading enzyme
151. Granule-associated flavin adenine dinucleotide (FAD) is responsible for eosinophil autofluorescence
152. Immunoelectron microscopic localization of catalase in human eosinophilic leukocytes
153. Urokinase localization and activity in isolated eosinophils
154. Histochemical demonstration of sulfated mucosubstances and cationic proteins in human granulocytes and platelets
155. Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor
156. Alpha-1-antitrypsin is present in the specific granules of human eosinophilic granulocytes